What is Aldacton (spironolactone), and what are the recommended starting dose, titration schedule, monitoring parameters, and contraindications for an adult patient without severe renal impairment?

Aldacton (Spironolactone): Dosing, Monitoring, and Contraindications

For adult patients without severe renal impairment, start spironolactone at 12.5-25 mg once daily, titrate to 25-50 mg daily after 4 weeks if tolerated, monitor potassium and renal function within 2-3 days and at 1 week after initiation, then monthly for 3 months, and avoid use if baseline potassium >5.0 mEq/L or creatinine >2.5 mg/dL in men or >2.0 mg/dL in women (eGFR <30 mL/min/1.73 m²). 1, 2

What is Aldacton?

Aldacton (spironolactone) is a potassium-sparing diuretic and aldosterone receptor antagonist used primarily for heart failure, hypertension, edema, and primary hyperaldosteronism. It blocks mineralocorticoid receptors in the distal tubule, reducing sodium-potassium exchange and providing mortality benefit in heart failure patients. 2

Starting Dose by Indication

Heart Failure (Most Common Use)

• Initial dose: 12.5-25 mg once daily 1, 2
• Requirements before starting: Potassium ≤5.0 mEq/L and eGFR >30 mL/min/1.73 m² 1, 2
• For eGFR 30-49 mL/min/1.73 m²: Consider 12.5-25 mg every other day due to hyperkalemia risk 1, 2

Hypertension

• Initial dose: 25-100 mg daily in single or divided doses 2
• Titrate at 2-week intervals; doses >100 mg/day provide minimal additional benefit 2

Primary Hyperaldosteronism

• Initial dose: 12.5-25 mg daily 3, 4
• May start higher (50 mg daily) if profound hypokalemia present 4
• Typical maintenance: 50-100 mg daily, occasionally up to 400 mg for surgical preparation 3, 2

Titration Schedule

The critical titration algorithm follows this sequence:

1. Week 0: Start 12.5-25 mg daily (or every other day if eGFR 30-49)
2. Days 2-3: Check potassium and creatinine 1, 2
3. Week 1: Recheck potassium and creatinine 1, 5, 2
4. Week 4: If potassium ≤5.0 mEq/L, increase to 25-50 mg daily 1, 6
5. Weeks 4-8: Recheck potassium and creatinine 1 and 4 weeks after dose increase 6
6. Months 1-3: Monthly potassium and creatinine monitoring 1, 5, 7
7. After 3 months: Every 3 months if stable 1, 6

The target maintenance dose for heart failure is 25-50 mg daily, with evidence-based maximum of 50 mg daily. 1, 6

Critical Monitoring Parameters

Laboratory Monitoring Timeline

• Before initiation: Potassium, creatinine, eGFR 1, 6
• 2-3 days after start: Potassium, creatinine 1, 2
• 1 week after start: Potassium, creatinine 1, 5, 2
• Monthly for first 3 months: Potassium, creatinine 1, 5, 7
• Every 3 months thereafter: Potassium, creatinine if stable 1, 6
• After any dose change or addition of ACE inhibitor/ARB: Restart monitoring cycle 1

Additional Monitoring

• Serum sodium, magnesium, calcium, uric acid, glucose periodically 2
• Volume status and blood pressure 2
• Watch for gynecomastia (9-10% incidence in men, dose-dependent, onset 1-2 months to >1 year) 6, 2

Absolute Contraindications

Do not use spironolactone if: 2

• Baseline potassium >5.0 mEq/L
• Creatinine >2.5 mg/dL in men or >2.0 mg/dL in women (eGFR <30 mL/min/1.73 m²) 1
• Addison's disease
• Concomitant use of eplerenone
• Pregnancy

Management of Hyperkalemia During Treatment

This is the most critical safety concern:

• Potassium 5.5-6.0 mEq/L: Halve the dose (e.g., 25 mg to 12.5 mg daily or 25 mg every other day), monitor closely 6
• Potassium ≥6.0 mEq/L: Stop spironolactone immediately, monitor closely, treat hyperkalemia 6, 2
• After resolution (K+ <5.0 mEq/L for ≥72 hours): Consider restarting at reduced dose 1

Essential Patient Counseling

Upon initiation, patients must: 1, 7

• Discontinue or reduce potassium supplements (unless history of severe hypokalemia requiring monitoring)
• Avoid high-potassium foods (bananas, oranges, salt substitutes)
• Avoid NSAIDs and COX-2 inhibitors (increase hyperkalemia and renal dysfunction risk)
• Report diarrhea or dehydration immediately (increases hyperkalemia risk)
• Take consistently with or without food 2

High-Risk Populations Requiring Extra Caution

Hyperkalemia risk increases with: 1, 5, 7

• Baseline creatinine >1.6 mg/dL (risk increases progressively)
• Elderly patients or low muscle mass (creatinine underestimates dysfunction)
• Concomitant ACE inhibitor dose ≥captopril 75 mg, enalapril/lisinopril ≥10 mg daily
• Diabetes mellitus (especially insulin-requiring)
• Concurrent nephrotoxic drugs (aminoglycosides, cisplatin, NSAIDs)

In these patients, start at 12.5 mg daily or every other day and monitor more frequently. 1, 7

Common Pitfalls to Avoid

1. Inadequate monitoring: 34% of patients in real-world practice receive no follow-up labs within 3 months, yet 15% develop hyperkalemia and 6% severe hyperkalemia 8
2. Continuing potassium supplements: Must discontinue or significantly reduce at initiation 1, 7
3. Using in patients with baseline creatinine >2.5 mg/dL: 63% develop hyperkalemia if baseline creatinine >2.5 mg/dL 8
4. Ignoring drug interactions: ACE inhibitors, ARBs, NSAIDs dramatically increase risk 1, 5, 2
5. Overlooking volume depletion: Can unmask renal dysfunction and precipitate hyperkalemia 7, 2

Renal Function Changes

Expect a decrease in GFR after starting spironolactone—this often represents treatment efficacy (reduced hyperfiltration) rather than toxicity, typically stabilizing long-term with renal-protective effects. 4 However:

• If creatinine rises to >2.5 mg/dL (220 μmol/L): Halve dose, monitor closely 6
• If creatinine rises to >3.5 mg/dL (310 μmol/L): Stop immediately 6